达沙替尼(Dasatinib) - 药物靶点：Bcr-Abl x EphA2 x FYN x LCK x PDGFRβ x Protein kinases x SRC x YES1 x c-Kit_在研适应症：费城染色体阳性慢性粒细胞白血病，费城染色体阳性急性淋巴细胞白血病，急性淋巴细胞白血病_专利_临床

概要

基本信息

药物类型

小分子化药

别名

anh. dasatinib、Anhydrous dasatinib、BMS dasatinib

+ [23]

靶点

Bcr-Abl x EphA2 x FYN x LCK x PDGFRβ x Protein kinases x SRC x YES1 x c-Kit

作用方式

抑制剂、拮抗剂

作用机制

Bcr-Abl抑制剂(bcr-abl酪氨酸激酶抑制剂)、EphA2拮抗剂(A型肝配蛋白受体-2拮抗剂)、FYN抑制剂(Fyn激酶抑制剂)

治疗领域

肿瘤免疫系统疾病血液及淋巴系统疾病+ [2]

在研适应症

费城染色体阳性慢性粒细胞白血病费城染色体阳性急性淋巴细胞白血病急性淋巴细胞白血病+ [9]

非在研适应症

肢端雀斑恶性黑色素瘤急性髓性白血病前列腺腺癌+ [69]

原研机构

Bristol Myers Squibb Co.

在研机构

Bristol Myers Squibb Co.Bristol-Myers Squibb Pharma EEIGAccord Healthcare SLU

+ [8]

非在研机构

Otsuka Pharmaceutical Development & Commercialization, Inc.

Celgene Corp.

OSI Pharmaceuticals, Inc.

+ [1]

最高研发阶段批准上市

首次获批日期

美国 (2006-06-28),

急性淋巴细胞白血病急性转化期慢性粒细胞性白血病慢性期慢性髓性白血病

最高研发阶段(中国)批准上市

特殊审评加速批准 (美国)、孤儿药 (美国)、孤儿药 (澳大利亚)、孤儿药 (日本)

登录后查看时间轴

结构/序列

分子式C22H28ClN7O3S

InChIKeyXHXFZZNHDVTMLI-UHFFFAOYSA-N

CAS号863127-77-9

关联

418

项与达沙替尼相关的临床试验

NCT05944783

/ Not yet recruiting临床4期

Bioequivalence Studies of Dasatinib 100 Mg Tablets in Healthy Colombian Subjects in Postprandial Condition

A bioequivalence study of Dasatinib will be carried out in 46 healthy subjects, in fed condition, following the complete replicated design, randomized, comparative of 2 sequences, 2 study formulations, in a single dose of 100 mg of Dasatinib tablets / coated tablets, 4 periods. , with a washout time of 7 days between each dose

开始日期2025-09-01

申办/合作机构-

NCT06124157

/ Not yet recruiting临床3期IIT

A Randomized International Phase 3 Trial of Imatinib and Chemotherapy With or Without Blinatumomab in Patients With Newly-Diagnosed Philadelphia Chromosome-Positive or Philadelphia Chromosome-Like ABL-Class B-Cell Acute Lymphoblastic Leukemia

This phase III trial compares the effect of the combination of blinatumomab with dasatinib and standard chemotherapy versus dasatinib and standard chemotherapy for treating patients with Philadelphia chromosome positive (PH+) or Philadelphia chromosome-like (Ph-Like) ABL-class B-Cell acute lymphoblastic leukemia (B-ALL). Blinatumomab is a bispecific antibody that binds to two different proteins-one on the surface of cancer cells and one on the surface of cells in the immune system. An antibody is a protein made by the immune system to help fight infections and other harmful processes/cells/molecules. Blinatumomab may bind to the cancer cell and a T cell (which plays a key role in the immune system's fighting response) at the same time. Blinatumomab may strengthen the immune system's ability to fight cancer cells by activating the body's own immune cells to destroy the tumor. Dasatinib is in a class of medications called tyrosine kinase inhibitors. It works by blocking the action of an abnormal protein that signals cancer cells to multiply, which may help keep cancer cells from growing. Giving blinatumomab and dasatinib in combination with standard chemotherapy may work better in treating patients with PH+ or Ph-Like ABL-class B-ALL compared to dasatinib and chemotherapy alone.

开始日期2025-05-29

申办/合作机构

National Cancer Institute

NCT06855810

/ Not yet recruiting临床2/3期IIT

Chinese Children's Cancer Group T-cell Acute Lymphoblastic Leukemia -2025 Project

This is a prospective, multicenter study conducted within the Chinese Children's Cancer Group (CCCG). The study aims to evaluate whether the addition of three novel agents, dasatinib, venetoclax and homoharringtonine, can improve the minimal residual disease (MRD)-negative remission rate, enhance event-free survival (EFS), and reduce the cumulative incidence of relapse (CIR) in pediatric patients with newly diagnosed T-cell acute lymphoblastic leukemia (T-ALL).

开始日期2025-03-01

申办/合作机构-

100 项与达沙替尼相关的临床结果

登录后查看更多信息

100 项与达沙替尼相关的转化医学

登录后查看更多信息

100 项与达沙替尼相关的专利（医药）

登录后查看更多信息

7,452

项与达沙替尼相关的文献（医药）

2025-12-31·Hematology

Second-line use of dasatinib and nilotinib in a real-world patient population with chronic phase chronic myeloid leukemia

Article

作者: Toptas, Tayfur ; Yilmaz, Asu Fergun ; Kaygusuz Atagunduz, Isik ; Menguc, Meral ; Demirtas, Derya ; Yanik, Ahmet Mert ; Candan, Ozlem ; Salim, Secil ; Tuglular, Tulin ; Arikan, Fatma

BACKGROUND:

While there has been no direct head-to-head comparison, it is assumed that second-line treatment with dasatinib and nilotinib has comparable efficacy but distinct safety profiles in the treatment of patients with chronic phase chronic myeloid leukemia (CML-CP). Our aim was to conduct a real-world analysis to compare the efficacy and safety profiles of these two agents.

METHODS:

Data from 73 CML-CP patients, who received either dasatinib or nilotinib in second-line treatment, were analyzed. The primary interest of the efficacy assessment was a major molecular response (MMR) at the 12-month, 5-year cumulative incidence of treatment failure, and overall survival.

RESULTS:

A total of 73.5% of 34 patients in the dasatinib and 76.9% of 39 patients in the nilotinib group achieved MMR at 12 months. Five-year cumulative probability of treatment failure in patients, who previously achieved MMR was 0 and 7.6% for patients receiving dasatinib and nilotinib, respectively (p = 0.25). Eight-year OS was 82.7 and 86.3% for dasatinib and nilotinib groups, respectively (p = 0.90). Pleural effusions were more common in the dasatinib group, leading to treatment discontinuation, while cardiovascular events and thrombotic incidents were more prevalent in the nilotinib group.

CONCLUSION:

Dasatinib and nilotinib exhibit similar efficacy in the CML-CP treatment. Individualized patient management should consider patient comorbidities and safety profiles.

2025-12-31·Animal Cells and Systems

Combination of dasatinib and quercetin promotes osteogenic differentiation and stemness maintenance of hPDLSCs via YAP/TAZ

Article

作者: Xiao, Han ; Qiu, Yunge ; Jia, Linglu ; Zhao, Yajun ; Sun, Shaoqing ; Wen, Yong ; Gu, Weiting

Human periodontal ligament stem cells (hPDLSCs) are candidate seed cells for periodontal tissue regeneration. Enhancing the stemness maintenance and osteogenic differentiation potential of hPDLSCs is conducive to their role in periodontal tissue regeneration. The combination of dasatinib and quercetin, a type of senolytic, has been reported to affect cell senescence. However, whether it can regulate the osteogenic differentiation and stemness maintenance of hPDLSCs, and the related mechanisms, remain unknown. The present study analyzed the optimal concentrations of dasatinib and quercetin in combination for hPDLSCs and found that the combination of dasatinib and quercetin enhanced osteogenic differentiation and promoted the expression of stemness-related markers in hPDLSCs. The expression levels of TAZ and YAP were improved when hPDLSCs were incubated with dasatinib and quercetin. However, the osteogenesis-promoting effects of dasatinib plus quercetin were partly attenuated when TAZ was knocked down, and their effects on stemness-related markers were suppressed when YAP was inhibited. Taken together, the combination of dasatinib and quercetin promotes the osteogenic differentiation and stemness maintenance of hPDLSCs, and YAP/TAZ may be involved in this process. This combination may hold promise for improving hPDLSCs function in periodontal tissue regeneration.

2025-05-01·EXPERIMENTAL PARASITOLOGY

In silico screening and molecular dynamic simulations of FDA-approved drugs as an inhibitor of trypanothione reductase of Leishmania donovani

Article

作者: Medhi, Bikash ; Prakash, Ajay ; Sehgal, Rakesh ; Bhusal, Chandra Kanta ; Beniwal, Pooja ; Choudhary, Gajendra ; Kaur, Sukhbir

Visceral leishmaniasis (VL) is mainly caused by Leishmania donovani (Ld) and Leishmania (L.) infantum, and it is prevalent in Brazil, India and East Africa. VL is a serious health issue, affecting millions of people worldwide and causing thousands of deaths annually. The current treatments for leishmaniasis are inadequate because of their low efficacy, toxicity and growing resistance, underscoring the pressing need to explore new drugs. Among the various molecular targets explored, trypanothione reductase (TR) is of special relevance because of its crucial function in regulating the parasite's redox homeostasis. Inhibiting TR can disrupt the redox homeostasis of the parasites, offering a promising strategy for developing new drugs with improved efficacy and safety profiles. In this study, 3D structure model of TR was elucidated by homology modelling and potential novel inhibitors against Leishmania donovani TR (LdTR) were identified by performing high-throughput virtual screening of 1615 FDA-approved drugs from the ZINC database via molecular docking, selecting top ligands on the basis of their high binding score and number of hydrogen bonds. These best hits are further subjected to Molecular Dynamics (MD) simulation and Molecular Mechanics Poisson- Boltzmann Surface Area (MM-PBSA) analysis. The results indicated that the binding scores of Dasatinib, Regorafenib, Bicalutamide, Raloxifene and Silodosin are -10.9 and -10.6, -10.1, -9.7 and -9.6 kcal/mol respectively. The lead compounds i.e. Dasatinib, Regorafenib, Bicalutamide, Raloxifene and Silodosin complexes with our target TR were found to be stable during MD simulation studies. Furthermore, MM-PBSA analysis demonstrated that these compounds had a high negative binding free energy. Thus, in-silico results showed that Dasatinib, Regorafenib, Bicalutamide and Raloxifene and Silodosin seem to have efficacy against TR for the treatment of VL. With further in vitro and in vivo investigations Dasatinib, Regorafenib, Bicalutamide, Raloxifene and Silodosin could be a good candidate of choice for combating leishmaniasis.

254

项与达沙替尼相关的新闻（医药）

2025-04-16

·PRNewswire

Penn Dental Medicine Study Finds New Therapy Shows Promise Against Periodontal Diseases

PHILADELPHIA, April 16, 2025 /PRNewswire/ -- Periodontal diseases, commonly known as gingivitis and periodontitis, remain a significant global health challenge, affecting nearly 60% of adults aged 65 and older and contributing to substantial medical, psychological, and financial burdens. Driven by a deregulated immune response to oral bacteria, chronic inflammation can not only lead to gum tissue destruction and tooth loss but also is linked to numerous systemic conditions. Researchers at Penn Dental Medicine discovered in an earlier clinical study that the chronic gum inflammation can promote an aging-related condition called "senescence," even in younger tissues. Senescent cells, which have permanently ceased to divide in response to stress, secrete inflammatory molecules that increase tissue damage, impair healing, and accelerate disease severity. Now, a new translational study by the same research team reveals that targeting senescent cell burden could be an effective strategy for managing periodontal disease and promoting oral health. In a paper recently published in the Journal of Dental Research, researchers showed that an anti-senescence therapy or "senotherapy," consisting of an enzyme inhibitor called dasatinib and a natural flavonoid plant compound called quercetin, reduced markers of senescence and associated periodontal inflammation and bone loss in lab-dish and animal models. "Our findings suggest that senotherapy offers a promising approach to preserving periodontal health," says Dr. Esra Sahingur of Penn Dental Medicine. "Periodontitis is more than a bacterial infection—it's driven by immune and metabolic dysfunction, cellular aging, and inflammation. By targeting inflammation and senescent cells, we may disrupt the chronic disease cycle and unlock new preventive and therapeutic possibilities for oral and systemic health." Sahingur and her team now hope to initiate an early-stage clinical trial to assess the effects of quercetin alone on biological and clinical markers in patients with gum diseases. She says that future clinical trials might also investigate the benefits of adding dasatinib at lower doses and intermittently to determine its safety and efficacy in periodontal applications. "Our hope is that these initial clinical trials will provide proof-of-concept for leveraging the therapeutic potential of natural products -- either as standalone agents or in combination regimens—as host modulatory strategies to enhance clinical outcomes in the management of periodontitis," Sahingur says. "If successful, this could lay the foundation for more targeted and effective treatments, particularly for patients at high risk of severe periodontal disease." Read more>> Media Contact: Beth Adams, [email protected] SOURCE PENN DENTAL MEDICINE WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

2025-04-13

·药事纵横

BMS, 默沙东, 辉瑞都将在未来三年里遭受专利悬崖的艰巨考验

在摩根大通医疗健康大会（J.P. Morgan Healthcare Conference，JPM）上，制药企业CEO们每年都需向投资者阐明其应对行业挑战的战略规划。2025年1月13日会议首日，百时美施贵宝（Bristol Myers Squibb）、辉瑞（Pfizer）和默沙东（Merck）三大药企的掌舵人针对专利悬崖问题发表了应对方案‌。百时美施贵宝首席执行官Chris Boerner率先提出“二维战略”框架。他预计，公司现有产品组合将持续面临“专利独占权丧失（LOE）风险”‌。其中，通过收购新基（Celgene）获得的重磅多发性骨髓瘤药物Revlimid®（来那度胺）将于2025年3月遭遇新一批仿制药竞争，并在2026年进入全面仿制药市场阶段‌。尽管明星抗凝药Eliquis®（阿哌沙班）在2024年前九个月创下44亿美元收入，但BMS预计该药物2025年销售额将"再降一级"至20-25亿美元区间。首席执行官Chris Boerner在JPM会议上指出，多发性骨髓瘤药物Pomalyst®（泊马度胺）与白血病药物Sprycel®（达沙替尼）也将于2025年遭遇仿制药冲击，形成"专利悬崖叠加效应"。这两款药物在2023年前九个月分别贡献27亿和10亿美元全球收入。面对收入威胁，BMS正通过研发管线突围。Boerner披露，公司目前有40个中后期研发项目推进中，预计到2025年新药组合将贡献超50%总收入。未来五年计划推出10款新药并实现30项适应症扩展，同时通过运营效率提升控制成本。Boerner强调："BMS有望在2030年前实现行业领先增长。"辉瑞首席执行官Albert Bourla在与摩根大通分析师的对话中坦言，公司正面临"明确的专利到期浪潮"。据最新年报披露，抗凝药Eliquis®、乳腺癌药物Ibrance®（帕博西尼）、前列腺癌药物Xtandi®（恩扎卢胺）等重磅产品将在2026-2028年间陆续失去专利保护，预计造成170-180亿美元年收入缺口。为填补收入缺口，辉瑞近年完成包括430亿美元收购Seagen在内的多笔交易。Bourla表示，并购资产预计在2030年前贡献200亿美元年收入，同时自研新药有望超越华尔街预期。该战略已初见成效，新冠药物Paxlovid®退潮后，RSV疫苗Abrysvo®和溃疡性结肠炎药物Velsipity®等新产品正快速上量。‌全行业最严峻的专利挑战当属默沙东的PD-1抑制剂Keytruda®（帕博利珠单抗）。这款2023年创下250亿美元销售额的"药王"，在2024年前九个月仍实现216亿美元收入。首席执行官Robert Davis在JPM会议上披露，自2021年以来，公司三期临床管线规模已扩大近三倍，期间通过战略合作投入约400亿美元。Davis强调："若未来2-3年能保持当前发展势头，我们完全有能力在Keytruda专利到期期间实现持续增长，而不仅仅是到期后的恢复。"目前，默沙东正通过HPV疫苗Gardasil®的产能扩张、15价肺炎疫苗Vaxneuvance®的市场渗透，以及收购Prometheus Biosciences获得的TL1A抗体等多元化布局构建"后Keytruda时代"护城河。药事纵横投稿须知：稿费已上调，欢迎投稿

并购专利到期疫苗

2025-03-17

·FiercePharma

The top 10 drugs losing US exclusivity in 2025

The end of the U.S. patent runway is nearing for 10 industry blockbusters in 2025. While each year features high-profile losses of exclusivity in the pharma industry, this year's list is something of a doozy.For one, Johnson & Johnson's Stelara is already facing off against several biosimilars, and several more are yet to come as the year plays out. With $6.72 billion in U.S. sales in 2024, the drug is the largest U.S. loss of exclusivity since AbbVie's megablockbuster Humira tumbled over the patent cliff in early 2023. Johnson & Johnson had previously warned of a "late 2023" patent cliff for Stelara, but the company was able to squeeze more life out of its key immunology moneymaker through a series of legal settlements.Johnson & Johnson's not alone in losing U.S. market exclusivity on a key sales driver this year. Also facing ongoing or future declines for their top revenue generators are Regeneron with eye drug Eylea, Amgen with bone medicines Prolia/Xgeva and Novartis with heart failure therapy Entresto. Eylea already faces its first U.S. biosimilar after Amgen launched Pavblu in November. Fierce Pharma chose to include Eylea in this report—despite the biosimilar launch happening last year—because the commercial situation is still playing out for Regeneron and to not exclude a key development in an important market.Amgen, for its part, collected $4.39 billion in revenue from its key bone medicines Prolia and Xgeva last year. While the company has built its own impressive biosimilar business over the years, it'll have to play an unfamiliar role and watch copycat drugs eat away at the market for its originators starting in late May and early June.Novartis, meanwhile, has warned of a "mid-2025" loss of U.S. exclusivity for Entresto as a key combination patent nears its expiration this summer. Besides Entresto, Novartis has two other big-selling products on this list in Promacta and Tasigna.Moving down the list, readers will likely notice two high-profile drugs from AstraZeneca. Rare disease medicine Soliris, picked up in AZ's buyout of Alexion, is set to face its first biosimilar from Amgen sometime in the second quarter. And Brilinta, a cardiometabolic drug once pegged to be a key blockbuster but that never quite met expectations, is also running out of its U.S. patent protections in the near future.For one measure of the high-profile nature of the drugs on this list, look no further than last year's version of the report. With $1.45 billion in prior-year U.S. sales, Bristol Myers Squibb's Sprycel led the 2024 group. But, if compared against the 2025 class of patent expirations, Sprycel would rank No. 6. There are always uncertainties in compiling this report due to the unpredictable nature of patent litigation and regulatory interactions. This year, the drug with the most apparent uncertainty is J&J's Simponi and Simponi ARIA. That medicine's inclusion hinges on a potential fourth-quarter approval—and launch—of Teva and Alvotech's AVT05. We opted to include the medicine because a key patent has already expired, and a reputable biosimilar team is marching through the regulatory process.To compile this report, Fierce Pharma parsed company filings, presentations and conference call transcripts. We also used published research from pharmacy benefit manager OptumRx and healthcare services firm Cardinal Health. The report ranks the top U.S. losses of exclusivity based on U.S. sales from the prior year.

专利到期专利侵权并购

100 项与达沙替尼相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D06414	达沙替尼	L01XE06	DB01254

研发状态

批准上市

10 条最早获批的记录,

登录

后查看更多信息

适应症	国家/地区	公司	日期
费城染色体阳性慢性粒细胞白血病	欧盟	Bristol-Myers Squibb Pharma EEIG	2006-11-20
费城染色体阳性慢性粒细胞白血病	冰岛	Bristol-Myers Squibb Pharma EEIG	2006-11-20
费城染色体阳性慢性粒细胞白血病	列支敦士登	Bristol-Myers Squibb Pharma EEIG	2006-11-20
费城染色体阳性慢性粒细胞白血病	挪威	Bristol-Myers Squibb Pharma EEIG	2006-11-20
费城染色体阳性急性淋巴细胞白血病	欧盟	Bristol-Myers Squibb Pharma EEIG	2006-11-20
费城染色体阳性急性淋巴细胞白血病	冰岛	Bristol-Myers Squibb Pharma EEIG	2006-11-20
费城染色体阳性急性淋巴细胞白血病	列支敦士登	Bristol-Myers Squibb Pharma EEIG	2006-11-20
费城染色体阳性急性淋巴细胞白血病	挪威	Bristol-Myers Squibb Pharma EEIG	2006-11-20
急性淋巴细胞白血病	美国	Bristol Myers Squibb Co.	2006-06-28
急性转化期慢性粒细胞性白血病	美国	Bristol Myers Squibb Co.	2006-06-28
慢性期慢性髓性白血病	美国	Bristol Myers Squibb Co.	2006-06-28

未上市

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
加速期慢性骨髄性白血病	申请上市	欧盟	Accord Healthcare SLU	2024-05-30
慢性粒细胞性白血病	申请上市	美国	Xspray Pharma AB	2021-11-18
去势抵抗性前列腺癌	临床3期	美国	Bristol Myers Squibb Co.	2008-10-01
去势抵抗性前列腺癌	临床3期	阿根廷	Bristol Myers Squibb Co.	2008-10-01
去势抵抗性前列腺癌	临床3期	澳大利亚	Bristol Myers Squibb Co.	2008-10-01
去势抵抗性前列腺癌	临床3期	巴西	Bristol Myers Squibb Co.	2008-10-01
去势抵抗性前列腺癌	临床3期	加拿大	Bristol Myers Squibb Co.	2008-10-01
去势抵抗性前列腺癌	临床3期	捷克	Bristol Myers Squibb Co.	2008-10-01
去势抵抗性前列腺癌	临床3期	芬兰	Bristol Myers Squibb Co.	2008-10-01
去势抵抗性前列腺癌	临床3期	法国	Bristol Myers Squibb Co.	2008-10-01

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


AACR2025	N/A	三阴性乳腺癌	-	Nebivolol	憲餘製繭窪夢廠繭襯簾(範壓獵積廠製廠廠醖範) = 範鏇構蓋願願艱蓋遞夢積廠築觸壓積獵餘獵築 (製築艱膚餘繭衊齋範夢 )	-	2025-04-27
				Dasatinib	憲餘製繭窪夢廠繭襯簾(範壓獵積廠製廠廠醖範) = 鹽窪餘築觸顧鏇製網遞積廠築觸壓積獵餘獵築 (製築艱膚餘繭衊齋範夢 )
NCT05422885 (STAMINA, CTgov)	临床1/2期	神经损伤 \| 阿尔茨海默症	15	Dasatinib+Quercetin	鹹遞壓鏇鹹網顧構蓋艱(繭遞鑰壓憲築醖鹽襯選) = 鏇簾構遞糧鏇蓋醖壓鹹願餘鏇鹹製繭顧襯醖糧 (選選觸鹹觸獵醖簾製鏇, 2) 更多	-	2025-03-17
NCT01254864 (CTgov)	临床2期	前列腺癌 \| 前列腺腺癌	190	Prednisone+Abiraterone Acetate	窪構廠艱繭網顧餘鏇衊(齋餘繭夢網築鹹膚積夢) = 蓋簾憲鬱膚願顧憲構繭壓憲廠膚衊範窪艱淵鹽 (製鏇選糧簾淵鬱窪簾遞, 淵夢鏇鹽淵膚憲選繭淵 ~ 憲積廠膚願齋簾膚壓蓋) 更多	-	2025-01-27
ASH2024	N/A	费城染色体阳性慢性粒细胞白血病	-	Nilotinib	鏇製衊鏇鏇觸鬱觸選淵(觸遞鑰遞繭襯襯衊醖襯) = increased creatinine and thyroid disease in flumatinib group 築鏇構鹹選範壓膚築壓 (醖遞繭簾選鹽膚簾願鑰 ) 更多	-	2024-12-09
				Dasatinib
ASH2024	N/A	费城染色体阳性急性淋巴细胞白血病	-	Dasatinib + Inotuzumab Ozogamicin	製壓鬱廠襯壓糧鬱餘廠(醖鬱餘顧艱齋築糧淵壓) = Grade 3-4 adverse events with incidence ≥10% were COVID19 (22%), dyspnea (22%), anemia (17%), fatigue (17%), anorexia (11%), bacteremia (11%), constipation (11%), elevated liver enzymes (11%), GI bleeding (11%), kidney injury (11%), vomiting (11%), and neutropenic fever (11%) 鏇遞鹽鑰餘鑰廠淵鹽襯 (願範夢鹽觸糧顧範鬱鑰 ) 更多	-	2024-12-07
NCT05198843 (CTgov)	临床1/2期	转移性乳腺癌 \| 转移性三阴性乳腺癌	1	Dasatinib+EPA	顧獵壓鑰顧築觸鑰願膚(鹹糧鹽餘淵願鏇壓網積) = 鑰齋壓觸憲構衊廠鬱範積繭襯夢積蓋繭鏇廠築 (簾範窪選鑰簾憲遞鹹遞, 蓋鑰餘蓋蓋醖鹽構鏇鏇 ~ 積觸觸淵窪構範範築顧) 更多	-	2024-09-04
NCT01467986 (RIST-rNB-2011, Pubmed) 人工标引	临床2期	神经母细胞瘤	129	dasatinib-rapamycin	鏇願鏇艱壓鑰範簾蓋衊(窪鬱鬱膚構願夢築餘願) = 膚淵醖願壓醖網餘糧網膚醖製繭選鹽觸鏇構齋 (膚積願膚窪醖齋艱鹽範, 7 ~ 17) 更多	积极	2024-07-01
				irinotecan-temozolomide	鏇願鏇艱壓鑰範簾蓋衊(窪鬱鬱膚構願夢築餘願) = 夢衊顧鹽構糧獵鑰鑰窪膚醖製繭選鹽觸鏇構齋 (膚積願膚窪醖齋艱鹽範, 2 ~ 8) 更多
ENDO2024	N/A	垂体肿瘤 DGKG	-	Dasatinib	膚鹽艱膚獵願憲醖繭餘(餘網網製艱網窪艱憲顧) = 遞齋鬱鑰艱夢獵膚淵夢壓窪夢構夢積築選鹽襯 (顧積鑰願願簾齋衊遞構 )	积极	2024-06-01
NCT06145217 (ASCO2024) 人工标引	临床1期	慢性期慢性髓性白血病	18	Crystalline Dasatinib	憲衊蓋繭糧構鹹衊鹽齋(窪築糧壓鬱廠壓構夢餘) = 觸鹹製鬱淵積窪淵齋鏇網願膚鏇積蓋鬱製築餘 (糧遞醖廠鬱鹽顧壓遞齋 ) 更多	不佳	2024-05-24
				Crystalline Dasatinib + Omeprazole	憲衊蓋繭糧構鹹衊鹽齋(窪築糧壓鬱廠壓構夢餘) = 膚簾淵淵夢淵艱膚構鹽網願膚鏇積蓋鬱製築餘 (糧遞醖廠鬱鹽顧壓遞齋 ) 更多
ASCO2024 人工标引	N/A	慢性期慢性髓性白血病	929	Dasatinib	蓋壓襯齋壓窪選餘齋鬱(觸顧淵積齋窪憲夢鏇願): RR = 1.24 (95% CI, 0.90 ~ 1.71), P-Value = 0.197 更多	积极	2024-05-24
				High-dose Imatinib